Mumbai, Dec. 22 -- India's pharmaceutical industry is stepping into 2026, marking the beginning of a critical five-year period to build the required ecosystem to establish itself as an innovation hub in its bid to become a USD 500 billion sector by 2047, amid near-term challenges of tariff fluctuations and global trade realignments.

The predominantly generic medicines-driven domestic drug industry grown from USD 3 billion to USD 60 billion in size over the past 25 years, is shifting towards innovation in next-generation drugs. Simultaneously, it aims to to capitalise on the opportunity to capture drugs worth over USD 300 billion that are set to lose exclusivity over the next seven years.

Published by HT Digital Content Services with per...